Medpacto: FDA approves amendment to Phase 1/2 IND for vactosertib monotherapy in relapsed, refractory or advanced osteosarcoma
AI reading
★★★★ Bullish · Material event
FDA approves change to osteosarcoma trial plan for vactosertib monotherapy
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
Other filings by Medpacto
- 10.02 ★★★ Australia clears Phase 1 clinical trial
- 09.18 ★★★ MedPacto seeks to amend Vactosertib Phase 1/2 trial protocol for osteosarcoma.
- 09.18 ★★ MedPacto files for MFDS approval to amend Phase 1/2 trial for Vactosertib in osteosarcoma patients.
- 09.18 ★★ MedPacto receives MFDS approval to amend Phase 1/2 trial for Vactosertib in osteosarcoma patients.
- 09.15 ★★★ MedPacto receives approval to amend Vactosertib monotherapy Phase 1/2 trial for osteosarcoma.
For information only. Not investment advice.